Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297830 · ClinicalTrials.gov registry record · Phase 2
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00297830 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 111 participants.
The verdict
NCT00297830, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion. Alendronate is given as a weekly pill. Both are expected to be very effective, but it is not known which one will work best.
Interventions
- DRUG Zoledronic acid
- DRUG Alendronate
- OTHER Placebo Zoledronic Acid
- OTHER Placebo Alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2005-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00297830
The ClinicalTrials.gov registry entry for NCT00297830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zoledronic acid is the first listed.
NCT00297830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00297830 about?
NCT00297830 is a clinical study titled "Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation". The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion. Alendronate is given as a weekly pill. Both are expected to be very effectiv...
What is the current status of trial NCT00297830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2005-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00297830?
The interventions under investigation include: Zoledronic acid (DRUG), Alendronate (DRUG), Placebo Zoledronic Acid (OTHER), Placebo Alendronate (OTHER).
Who is sponsoring clinical trial NCT00297830?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.